This continuing feature will update readers on recent developments in cardiovascular pharmacotherapy. Cardiovascular disease remains the number one killer in the United States, and more clinical outcome trials have been conducted in cardiology than in any other field of medicine. Given this rapidly expanding knowledge base, pharmacists can have a significant impact on prevention and treatment—if they keep current with developments in drug therapy.
Get full access to this article
View all access options for this article.
References
1.
ThomT., HaaseN., Rosamond. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation.2006; 113: e85–e151.
2.
AbramsJ.Chronic stable angina. N Engl J Med.2005; 352: 2524–2533.
3.
KempfJ., ShettyS., NelsonM.Resource utilization and cost of care for chronic stable angina in the United States (abstract). Circulation.2006; 113: e810.
4.
ChaitmanB.R., SkettinoS.L., ParkerJ.O.. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol.2004; 43: 1375–1382.
5.
ChaitmanB.R., PepineC.J., ParkerJ.O.. for the Combination Assessment of Ranolazine in Stable Angina (CARISA) Investigators. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with chronic stable angina, a randomized controlled trial. JAMA.2004; 291: 309–316.
6.
BelardinelliL., AntzelevitchC., FraserH.Inhibition of late (sustained/persistent) sodium current: a potential drug target to reduce intracellular sodium-dependent calcium overload and its detrimental effects on cardiomyocyte function. Eur Heart J.2004; 6(Suppl 1): 13–17.
7.
AntzelevitchC., BelardinelliL., ZygmuntA.C.. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation.2004; 110: 904–910.
8.
TafreshiM.J., FisherE.Ranolazine: a new approach to management of patients with angina. Ann Pharmacother.2006; 40: 689–693.
9.
GaffneyS.M.Ranolazine, a novel agent for chronic stable angina. Pharmacotherapy.2006; 26: 135–142.
10.
SiddiquiA.M., KeamS.J.Ranolazine a review of its use in chronic stable angina pectoris. Drugs.2006; 66: 693–710.
11.
ChaitmanB.R.Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions. Circulation.2006; 113: 2462–2472.
12.
JerlingM., AbdallahH.Effect of renal impairment on multiple-dose pharmacokinetics of extended-release ranolazine. Clin Pharmacol Ther.2005; 78: 288–297.
13.
AbdallahH., JerlingM.Effect of hepatic impairment on multiple-dose pharmacokinetics of extended-release ranolazine. Clin Pharmacol.2005; 45: 802–809.
14.
PepineC.J., WolffA.A.A controlled trial with a novel antiischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents: ranolazine study group. Am J Cardiol.1999; 84: 46–50.
15.
ThadaniU., EzekowitzM., FenneyL., ChiangY.K.Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris: ranolazine study group. Circulation.1994; 90: 726–734.
16.
RousseauM.F., PouleurH., CoccoG., WolffA.A.Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am J Cardiol.2005; 95: 311–316.
17.
CoccoG., RousseauM.F., BouvyT.. Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with beta-blocker or diltiazem. J Cardiovasc Pharmacol.1992; 20: 131–138.
18.
ChaitmanB.R.Measuring antianginal drug efficacy using exercise testing for chronic angina: improved exercise performance with ranolazine, a pFOX inhibitor. Curr Probl Cardiol.2002; 12: 527–555.
StoneP.H., GratsianskiN.A., BlokhinA.on behalf of the ERICA Investigators. Anti-anginal efficacy of ranolazine when added to maximal therapy with conventional therapy: the Efficacy of Ranolazine in Chronic Angina trial (Abstract No 3491). Circulation.2005; 112(Suppl 2): 748–749.
21.
SpertusJ.A., WinderJ.A., DewhurstT.A.. Development and evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary artery disease. J Am Coll Cardiol.1995; 25: 333–341.
22.
TimmisA.D., ChaitmanB.R., CragerM.Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart J.2006; 27: 42–48.
Al-KhatibS.M., LaPointeN.M., KramerJ.M., CaliffR.M.What clinicians should know about the QT interval. JAMA.2003; 289: 2120–2127.
25.
CrouchM.A., LimonL., CassanoA.T.Clinical relevance and management of drug-related QT interval prolongation. Pharmacotherapy.2003; 23: 881–908.
26.
The University of Arizona Center for Education and Research on Therapeutics. International registry for drug-induced arrhythmias. Available at: http://www.torsades.org. Accessed May 24, 2006.
